Objective To evaluate the inhibitory effect of Lactobacillus plantarum mouthwash on the progression of caries in isolated teeth.Methods Human isolated teeth were infected with Streptococcus mutans solution,and treated with saline,commercial mouth-wash,and Lactobacillus plantarum mouthwash,respectively,for 28 days.Tooth changes were recorded to assess their inhibitory effect on caries progression by light microscopy and scanning electron microscopy.Results Lactobacillus plantarum had an inhibitory effect on caries progression,with significant effects on deep dentinal caries in pit and fissure,and similar efficacy to commercial mouthwash on smooth surface caries.Calcium loss in dentin tubules was observed under an electron microscope,with Lactobacillus plantarum group less than commercial group and saline group.Conclusion Lactobacillus plantarum mouthwash can inhibit the growth of Streptococcus mutans and effectively prevent caries,particularly in controlling the progression of deep pit and fissure caries.

Objective To evaluate the inhibitory effect of Lactobacillus plantarum mouthwash on the progression of caries in isolated teeth.Methods Human isolated teeth were infected with Streptococcus mutans solution,and treated with saline,commercial mouth-wash,and Lactobacillus plantarum mouthwash,respectively,for 28 days.Tooth changes were recorded to assess their inhibitory effect on caries progression by light microscopy and scanning electron microscopy.Results Lactobacillus plantarum had an inhibitory effect on caries progression,with significant effects on deep dentinal caries in pit and fissure,and similar efficacy to commercial mouthwash on smooth surface caries.Calcium loss in dentin tubules was observed under an electron microscope,with Lactobacillus plantarum group less than commercial group and saline group.Conclusion Lactobacillus plantarum mouthwash can inhibit the growth of Streptococcus mutans and effectively prevent caries,particularly in controlling the progression of deep pit and fissure caries.

Objective To determine the mutant status of BRAF gene in Chinese colorectal cancer (CRC) patients and analyze the association with clinicopathological parameters.Methods 676 CRC samples were collected in Cancer Institute/ Hospital,Chinese Academy of Medical Science from December 2009 to December 2011.The direct sequencing was conducted to detect mutations in the BRAF (exon 15 and exon 11).The correlation between mutant status with clinicopathological parameters were analyzed.Results Beside 10 colorectal cancer samples,among the 666 colorectal cancer patients 4.35％ (29/666) of the tumors harbored a BRAF mutation,of which 1.94％ (13/669) in exon 15 (V600E),2.39％ (16/670) in exon 11.Statistical analysis revealed that BRAF15 mutations appeared to occur more frequently in poor-differentiation tumors than high or moderate-differentiation tumors (5.81％ vs 1.46％,r =0.105,P=0.040).But BRAF15 mutations were not correlated with age,gender,smoking and drinking history,tumor site,tumor type,tumor(T/N) staging,histological type,or distant metastasis [r equals to 0.007,-0.018,-0.049,-0.023,-0.098,-0.038,0.040(0.034/0.059),0.065,0.042,respectively,P ＞ 0.05] ; BRAF11 mutations appeared to occur more frequently in patients with drinking history (6.02％vs 1.81％,r =0.093,P =0.035).However,age,gender,smoking history,tumor site,tumor type,tumor differentiation,tumor(N) staging,histological type,or distant metastasis showed no significant correlation with this mutation [r equals to-0.004,0.047,0.020,0.042,0.029,0.040,0.006 (-0.008),0.008,0.030,respectively,P ＞ 0.05].Conclusion A higher proportion of BRAF15 (V600E) mutations occurred in poor-differentiation tumors among the Chinese patients with CRC; BRAF11 mutations appeared more frequently in patients with drinking history.

Objective To evaluate clinical application of Jin Pujia GP HER2 probe kit in testing HER2 gene status of breast cancer through comparing it with PathVysion HER2 probe kit. Methods HER2 gene status were detected from 108 cases with invasive ductal breast cancer using GP and PathVysion HER2 probe kits by FISH. HER2 gene expression levels were measured by GP and PathVysion HER2 probe kits, and the sensitivity, the specificity and the accuracy of GP HER2 probe kit were evaluated. Results HER2 gene amplification positive rates detected by GP HER2 probe kit and PathVysion HER2 probe kit were 25.0%(27/108) and 26.9% (29/108), respectively. As compared with PathVysion HER2 probe kit, the sensitivity, the specificity and the accuracy of the GP HER2 kit were 89. 7% (26/29), 98.7% (78/79)and 96. 3% ( 104/108), respectively, whereas the PPV and NPV were 96. 3% (26/27) and 96. 3% (78/81), respectively. The GP HER2 probe kit had a sensitivity of 93.3% ( 14/15), a specificity of 100%(93/93) and an accuracy of 99. 1% (107/108) for detecting polysomy 17. Conclusion GP HER2 probe kit has high sensitivity and specificity for detecting HER2 gene status in breast cancer patients, and it has clinical application value.